GOSSELIES, Wallonia, Belgium–TheraVet’s BIOCERA-VET® was evaluated in a prospective non-controlled multicentric clinical research in client-owned dogs with osteosarcoma. 12 dogs were treated with a percutaneous cimentoplasty as a palliative therapy for the disease. After one month, 67 percent of the dogs reported a reduction in discomfort of at least 50 percent. Quality of life was enhanced in 78% of the animals after one month and 50% after two and six months. The same decrease levels were detected with the CBPI’s pain severity (PSS) and pain interference with function (PIF) ratings, but somewhat less4. For more information, visit the TheraVet.
Read the full press release at Business Wire